The company has engineered a dual-specificity antibody fragment designed to activate IL-12 selectively in the tumour microenvironment, with preclinical data and quantitative systems pharmacology modelling indicating potential for reduced systemic toxicity
The company has engineered a dual-specificity antibody fragment designed to activate IL-12 selectively in the tumour microenvironment, with preclinical data and quantitative systems pharmacology modelling indicating potential for reduced systemic toxicityThis article was originally published by Manufacturing Chemist.
Read Full Story on Source Site →
